Dr. Mona Jhaveri founded Music Beats Cancer to support cancer research and address the severe funding gap that commonly forces entrepreneurs advancing cancer-fighting inventions to abandon their work.501(c)3 charity Music Beats Cancer has partnered with Singh Biotechnology (SBT) in a charitable crowdfunding campaign to help combat pancreatic cancer.Music Beats Cancer, a 501(c)3 charity, has partnered with Singh Biotechnology (SBT) in a charitable crowdfunding campaign to help combat pancreatic cancer. Music Beats Cancer will match donations that SBT raises up to $12,500 after the campaign concludes on April 15, 2022, at 11:59 a.m. EST.
“Pancreatic cancer remains one of the deadliest cancers worldwide,” said Dr. Mona Jhaveri, founder of Music Beats Cancer. “Progress over the past decades has been modest because effective treatments have yet to surface. SBT's lead drug candidate, SBT-100, could be a game-changer.”
Music Beats Cancer utilizes charitable crowdfunding to support cancer-fighting innovation and research, increasing the number of cancer-fighting technologies in the product development pipeline. The nonprofit supports the advancement of new solutions for cancer so more treatments reach those in need. This addresses the “Valley of Death,” the severe funding gap that commonly forces entrepreneurs advancing cancer-fighting inventions to abandon their work. Most of these projects will fail before they get a chance to prove themselves due to lack of funding.
SBT is developing a new treatment approach that may stop cancer growth. The company’s drugs achieve this by forcing cells into the “off position,” shutting down all cellular pathways for growth and leaving cancer cells unable to work around it. This process is similar to shutting off the master switch of an electric circuit breaker box.
SBT’s proprietary technology can also permeate all cells without harming normal ones, which has been traditionally difficult to do in organs like the brain and eyes. This could revolutionize how deadly cancers, including pancreatic, are treated. SBT’s lead drug candidate, SBT-100, has already shown preliminary success in animal models for multiple cancers.
"Developing non-toxic and curative medicines to stop the proliferation of hard-to-treat cancers, such as pancreatic, is within reach," said Dr. Saundra Singh, founder of SBT. “Our approach has been shown to be highly effective in animal models for various cancer types, including pancreatic cancer.”
The funds raised for Music Beats Cancer’s campaign will contribute to SBT’s crucial research and testing measures. These include: conducting two animal toxicology, safety, and efficacy studies; determining the best Liquid Chromatography-Mass Spectrometry (LCMS) bio-analytical method of drug analysis; developing CMC (Chemistry, Manufacturing, and Controls) to produce their drug, SBT-100, under good manufacturing practice conditions for investigational new drug (IND) enabling studies; paying investigational new drug application fees; and entering into phase one clinical trials, as well as covering ancillary expenses.
#MusicBeatsCancer #PancreaticCancer #SinghBiotechnology #Crowdfunding #CancerResearch #CancerTreatment #CancerInnovation
For more information, interviews, and other media requests, please contact david.watkins@otterpr.com and visit Music Beats Cancer.
Media Contact
Company Name: Otter PR
Contact Person: David Watkins
Email: Send Email
Phone: 2076712693
Address:100 E Pine St Suite 110
City: Orlando
State: FL
Country: United States
Website: www.OtterPR.com
